Patient Profile

Suitable Candidates

  • Patients with a steroid responsive skin condition who don’t require a potent or very potent topical corticosteroid

Unsuitable Candidates

  • Patients with a known hypersensitivity to the topical corticosteroid or to the vehicle
  • Patients with mycobacterial, fungal, and/or viral infections
  • Patients with scabies or pediculosis
  • Patients with chronic ulcers
  • Avoid treatment of rosacea and perioral dermatitis. Topical corticosteroids may initially provide improvement, but severe rebound flare-up may occur upon discontinuance.
  • Should not be used for the treatment of acne.
  • Should not be used for routine gingivitis. This should be treated by removing the local causative factors and improving oral hygiene.


  • suitable for the treatment of mild-to-moderate AD.
  • unique gentle cream base with moisturizing properties.
  • best for short-term treatment of extensive dermatoses.
  • best used on the trunk and extremities.
  • safer for short-term use on thin skin; it is less effective on thicker skin.
  • should be applied 2-3 times daily according to the severity of condition.
  • should be used to bring flare-ups of eczema under control.
  • can be used intermittently long-term, e.g., weekends only, to prevent relapses.
  • should be used in combination with moisturizers.
  • can be used in combination with other drugs.

Frequency of Application:

  • Apply thinly 2-3 times per day (according to the severity of the condition) to the affected area and rub gently into the skin. Maximum adult dosage should not exceed 100 g/week.

[CPS. The Canadian Drug Reference for Health Professionals. Ottawa: Canadian Pharmaceutical Association (2003).]

General Guidelines for Eumovate® Cream vs. Ointment

PreparationMoisturizing vs. Drying/ CosmesisPreferred DermatosesPreferred Location for UsePotential for Irritation
Ointment – water in oilMore occlusive than Eumovate® cream/very greasy feelBest for thick, lichenified or scaly dermatosesBest for thick palmar or plantar skin; avoid occluded areasGenerally low
Cream – oil in waterModerate in moisturizing tendency/ ElegantBest for acute, subacute, or weeping dermatosesGood for moist skin and intertriginous areasVariable; requires preservatives



    • Clobetasone butyrate 0.05% cream with its moisturizing emollient base is reported to provide better healing properties than hydrocortisone 1% cream. Its high glycerol content promotes skin hydration and protects and moisturizes the skin.

[J Dermatol Treat. 2001 Dec;12(4):191-7.]

  • has no demonstrated potential for skin thinning vs. 1% hydrocortisone.
    [GSK product monograph]
  • has negligible systemic absorption and effect on HOP axis function.
    [GSK product monograph]
  • has minimal side effects even in children under 2.
    [GSK product monograph]
  • has a high glycerol content which promotes skin hydration and absorption.
    [J Dermatol Treat. 2001 Dec; 12(4):191-7.]
  • contains dimethicone to protect and moisturize the skin.
    [J Dermatol Treat. 2001 Dec; 12(4):191-7.]
  • The emollient base used for Eumovate® cream offers better healing properties than 1% hydrocortisone.
    [J Dermatol Treat. 2001 Dec; 12(4):191-7.]


  • Reasons for treatment failure in atopic eczema:
    • failure to use the topical corticosteroid due to fear of real or imagined side-effects
    • under prescribing/failure to use sufficient quantity
    • failure to renew prescription in time.
  • It is very important that patients/caregivers understand the safety and potential side effects for moderate potency topical corticosteroids such as Eumovate®. Misconceptions about commonly prescribed topical corticosteroid preparations among parents/caregivers include:
      • 44% graded hydrocortisone as a potent steroid.
      • 42% did not grade betamethasone valerate 0.1% as potent.
      • 29% graded clobetasone butyrate 0.05% (Eumovate®) as potent.
      • 12% graded clobetasone butyrate 0.05% (Eumovate®) as weak.

[Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of atopic dermatitis. Clin Exp Dermatol. 2003 Sep;28(5):549-53.]

  • Patient education on topical steroids is clearly needed

Cost of Treatment


Moderately PotentModerately PotentMildly PotentPotentNon-steroidalNon-steroidal
Eumovate Clobetasone butyrate (2x daily)Cyclocort Amcinonide (2x daily)Cortate Hydrocortisone 1% (3x daily)Elocom Mometasone Furoate (1x daily)Protopic† Tacrolimus (2x daily)Elidel †.Pimecrolimus (2x daily)